“One-shot” combined therapy with oral ivermectin and local benzyl benzoate: is the current best therapeutic option in the era of permethrin resistant scabies?

Bassi, Andrea; Piccolo, Vincenzo; Mazzatenta, Carlo

doi:10.1016/j.tmaid.2023.102585

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, it seems necessary to change or at least modify the first-line treatment of scabies [11]. Combined therapy with oral ivermectin and topical benzyl benzoate seems to be the best therapeutic approach, with 100% treatment success in newly diagnosed patients and patients unresponsive to permethrin [12]. In infants weighing less than 15 kg, topical ivermectin is recommended [13].…”

Section: Discussionmentioning

confidence: 99%

Factors Affecting Topical Treatment Success in Pediatric Scabies Cases: A Cross-Sectional Study

Oba,

Özkoca,

Başara Şahin

et al. 2023

Dermatol Pract Concept

View full text Add to dashboard Cite

Introduction: Scabies is a common disease affecting the pediatric population. Treatment failure and relapses are frequent. Objectives: We aimed to define factors affecting topical treatment success in pediatric scabies patients. Methods: This multicenter cross-sectional study was performed between April and December 2022. Pediatric scabies cases were classified as treatment failure (TF) versus treatment success (TS). Results: We enrolled 170 patients in the study. In the TF group, the presence of symptomatic household members and referral from physicians other than dermatologists were more common (both p<0,001) and relapse rates and total symptom duration were higher (p=0,007, p<0,001 respectively). Permethrin 5% was more commonly used in the TF group (71.1% versus 25%) (p<0,001); however, the ratio of patients treated with sulfur preparations was significantly higher in the TS group (60.7% vs 16.9%) (p<0,001). Misapplication of topical therapy was significantly more common in the TF group (p<0,001), statistically significant errors being: (i) lack of treatment of close contacts (p<0,001); (ii) single application (p<0,001); and (iii) local application (p=0,027). In a multivariate analysis, treatment success was mainly associated with (i) presence of atopy (O.R.: 5,29, 95% CI: 1,22-25,57) ;(ii) absence of symptomatic household members (O.R.: 5,29, 95% CI: 1,72-16,27); (iii) presentation to dermatologists rather than other specialties (O.R.: 6,08, 95% CI: 1,9-19,51); whereas use of permethrin negatively affected treatment success (O.R: 0,22, 95% CI: 0,07-0,71). Conclusions: Pediatric scabies patients should be treated before other family members get affected and with topicals other than permethrin. Awareness of scabies disease needs to be increased among non-dermatologists.

show abstract

Section: Discussionmentioning

confidence: 99%

Factors Affecting Topical Treatment Success in Pediatric Scabies Cases: A Cross-Sectional Study

Oba,

Özkoca,

Başara Şahin

et al. 2023

Dermatol Pract Concept

View full text Add to dashboard Cite

show abstract

Effective and safe use of benzyl benzoate in young children at the same concentrations as adults: A matter of vehicle?

Bassi,

Piccolo,

Argenziano

et al. 2024

Acad Dermatol Venereol

View full text Add to dashboard Cite

Escalating Threat of Drug-Resistant Human Scabies: Current Insights and Future Directions

Simonart,

Lam Hoai

2024

JCM

View full text Add to dashboard Cite

Background: Scabies is a prevalent dermatological condition with significant public health implications. The recent rise in drug-resistant scabies presents new challenges for effective disease management and control. Methods: A comprehensive literature review was conducted using PubMed, Cochrane Library, and Web of Science. Studies published from 2000 to August 2024 were considered, focusing on those reporting drug-resistant scabies and advancements in treatment approaches. Results: Clinical studies, in vitro investigations, and case reports show significant resistance of human scabies to permethrin. Main resistance mechanisms involve genetic mutations in the mites’ voltage-gated sodium channels (VGSCs) and enhanced activity or expression of the detoxifying enzyme glutathione S-transferase (GST). Resistance to ivermectin and benzyle benzoate, although suggested by some authors, seems less obvious. The clinical evidence of widespread ivermectin resistance in human scabies infestations is lacking, despite indications of increased tolerance in laboratory settings and anecdotal reports of resistance in patients with crusted scabies. Benzyl benzoate resistance in scabies mites remains unconfirmed. Conclusions: Permethrin-resistant scabies is an escalating threat requiring new management strategies and updated guidelines. Infection control measures, alternative treatments, and ongoing research into new therapeutics are crucial to mitigate the impact of drug-resistant scabies.

show abstract

“One-shot” combined therapy with oral ivermectin and local benzyl benzoate: is the current best therapeutic option in the era of permethrin resistant scabies?

Cited by 3 publications

References 9 publications

Factors Affecting Topical Treatment Success in Pediatric Scabies Cases: A Cross-Sectional Study

Factors Affecting Topical Treatment Success in Pediatric Scabies Cases: A Cross-Sectional Study

Effective and safe use of benzyl benzoate in young children at the same concentrations as adults: A matter of vehicle?

Escalating Threat of Drug-Resistant Human Scabies: Current Insights and Future Directions

Contact Info

Product

Resources

About